Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aegerion Expands Global Commercial Team
Company Adds Mark A. Rothera as Global President
View HTML
Toggle Summary Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced the primary endpoint was achieved in the
View HTML
Toggle Summary Aegerion Pharmaceuticals Acknowledges the National Lipid Association's Revised Guidelines for the Treatment of Familial Hypercholesterolemia
CAMBRIDGE, Mass., April 14, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc . (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today acknowledged the publication of the National Lipid
View HTML
Toggle Summary Aegerion Pharmaceuticals Acquires Myalept™ From AstraZeneca
Conference Call to be Held at 8:00 a.m. EST Today
View HTML
Toggle Summary Aegerion Pharmaceuticals Adds to Management Team Anne Marie Cook as SVP, General Counsel, and Mary Weger as SVP, Human Resources
CAMBRIDGE, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the appointment of Anne Marie Cook as Senior Vice
View HTML
Toggle Summary Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need-- --Broad-Based Investor Syndicate to Vote in Favor of
View HTML
Toggle Summary Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger   --Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile
Results Will Be Presented Today At AHA Conference in Orlando, Florida
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors
CAMBRIDGE, Mass., July 21, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the appointment of Paul G.
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Appointment of Sol J. Barer, Ph.D. to Board of Directors
CAMBRIDGE, Mass., April 19, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.  (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the appointment of Sol J.
View HTML